Beranda › Kanker Saluran Empedu
Uji klinis Kanker Saluran Empedu yang merekrut di AS
40 studi untuk Kanker Saluran Empedu merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX18 studi
- Los Angeles, CA11 studi
- Boston, MA11 studi
- New York City, NY10 studi
- Nashville, TN9 studi
- San Antonio, TX8 studi
- Baltimore, MD8 studi
- Washington, DC7 studi
- Arlington, VA7 studi
- Pittsburgh, PA7 studi
- Baldwin Park, CA6 studi
- Cleveland, OH6 studi
- Dallas, TX6 studi
- Columbus, OH6 studi
- Madison, WI6 studi
- Philadelphia, PA6 studi
- Detroit, MI5 studi
- Louisville, KY5 studi
- Tampa, FL5 studi
- Miami, FL5 studi
- Orange, CA4 studi
- Seattle, WA4 studi
- Aurora, CO4 studi
- Queens, NY4 studi
- Orlando, FL4 studi
- Buffalo, NY3 studi
- Edison, NJ3 studi
- Santa Monica, CA3 studi
- Salt Lake City, UT3 studi
- St. Louis, MO3 studi
- San Diego, CA3 studi
- Grand Rapids, MI3 studi
- Chicago, IL3 studi
- Tucson, AZ3 studi
- Providence, RI3 studi
- Denver, CO3 studi
- Portland, OR3 studi
- Birmingham, AL3 studi
Berdasarkan negara bagian
- Alabama3 studi
- Arizona4 studi
- California20 studi
- Colorado7 studi
- Connecticut3 studi
- Distrik Columbia4 studi
- Florida14 studi
- Georgia4 studi
- Illinois5 studi
- Kentucky6 studi
- Maryland11 studi
- Massachusetts11 studi
- Michigan9 studi
- Minnesota5 studi
- Missouri4 studi
- New Jersey5 studi
- New York15 studi
- Ohio10 studi
- Oregon3 studi
- Pennsylvania10 studi
- Rhode Island3 studi
- Tennessee10 studi
- Texas23 studi
- Utah4 studi
- Virginia9 studi
- Washington5 studi
- Wisconsin6 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Menerima pesertaStudi observasional
Usia 2 hingga 100 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT01950572A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Sep 2026 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06428409Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05523947Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Menerima pesertaFase 2
Usia 18 hingga 130 · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT05489211Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Menerima pesertaFase 2
Usia 19 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07146646Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT06282575SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07812805Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT06293898CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT06548412AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Menerima pesertaFase 1/2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT07038343Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT06084481Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 24 Agu 2026 · NCT05517811A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Menerima pesertaFase 3
Usia 18 hingga 99 · Semua jenis kelamin · Diperbarui 19 Agu 2026 · NCT06467357A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05592626A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06330064D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT06622057A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Menerima pesertaFase 2
Usia 8 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT05503797Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT06101277A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT07458347Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.